637 related articles for article (PubMed ID: 22454060)
21. Viltolarsen for the treatment of Duchenne muscular dystrophy.
Roshmi RR; Yokota T
Drugs Today (Barc); 2019 Oct; 55(10):627-639. PubMed ID: 31720560
[TBL] [Abstract][Full Text] [Related]
22. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
[TBL] [Abstract][Full Text] [Related]
23. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
24. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
[TBL] [Abstract][Full Text] [Related]
25. Exons 45-55 Skipping Using Antisense Oligonucleotides in Immortalized Human DMD Muscle Cells.
He M; Yokota T
Methods Mol Biol; 2023; 2640():313-325. PubMed ID: 36995604
[TBL] [Abstract][Full Text] [Related]
26. Splicing intervention for Duchenne muscular dystrophy.
McClorey G; Fletcher S; Wilton S
Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
[TBL] [Abstract][Full Text] [Related]
27. Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene.
Echigoya Y; Lim KRQ; Melo D; Bao B; Trieu N; Mizobe Y; Maruyama R; Mamchaoui K; Tanihata J; Aoki Y; Takeda S; Mouly V; Duddy W; Yokota T
Mol Ther; 2019 Nov; 27(11):2005-2017. PubMed ID: 31416775
[TBL] [Abstract][Full Text] [Related]
28. Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries.
Adams AM; Harding PL; Iversen PL; Coleman C; Fletcher S; Wilton SD
BMC Mol Biol; 2007 Jul; 8():57. PubMed ID: 17601349
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.
Lim KRQ; Echigoya Y; Nagata T; Kuraoka M; Kobayashi M; Aoki Y; Partridge T; Maruyama R; Takeda S; Yokota T
Mol Ther; 2019 Jan; 27(1):76-86. PubMed ID: 30448197
[TBL] [Abstract][Full Text] [Related]
30. In Vivo Evaluation of Single-Exon and Multiexon Skipping in mdx52 Mice.
Mizobe Y; Miyatake S; Takizawa H; Hara Y; Yokota T; Nakamura A; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1828():275-292. PubMed ID: 30171548
[TBL] [Abstract][Full Text] [Related]
31. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
[TBL] [Abstract][Full Text] [Related]
32. Exon-skipping therapy for Duchenne muscular dystrophy.
Nakamura A; Takeda S
Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
[TBL] [Abstract][Full Text] [Related]
33. Optimizing splice-switching oligomer sequences using 2'-O-methyl phosphorothioate chemistry.
Adkin C; Fletcher S; Wilton SD
Methods Mol Biol; 2012; 867():169-88. PubMed ID: 22454061
[TBL] [Abstract][Full Text] [Related]
34. Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle.
Takeshima Y; Yagi M; Wada H; Matsuo M
Brain Dev; 2005 Oct; 27(7):488-93. PubMed ID: 16198206
[TBL] [Abstract][Full Text] [Related]
35. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons.
Aartsma-Rus A; Kaman WE; Weij R; den Dunnen JT; van Ommen GJ; van Deutekom JC
Mol Ther; 2006 Sep; 14(3):401-7. PubMed ID: 16753346
[TBL] [Abstract][Full Text] [Related]
36. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
[TBL] [Abstract][Full Text] [Related]
37. Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy.
Yokota T; Hoffman E; Takeda S
Methods Mol Biol; 2011; 709():299-312. PubMed ID: 21194037
[TBL] [Abstract][Full Text] [Related]
38. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping.
Mitrpant C; Fletcher S; Iversen PL; Wilton SD
J Gene Med; 2009 Jan; 11(1):46-56. PubMed ID: 19006096
[TBL] [Abstract][Full Text] [Related]
39. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
Anthony K; Arechavala-Gomeza V; Ricotti V; Torelli S; Feng L; Janghra N; Tasca G; Guglieri M; Barresi R; Armaroli A; Ferlini A; Bushby K; Straub V; Ricci E; Sewry C; Morgan J; Muntoni F
JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
[TBL] [Abstract][Full Text] [Related]
40. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy.
Takeshima Y; Yagi M; Wada H; Ishibashi K; Nishiyama A; Kakumoto M; Sakaeda T; Saura R; Okumura K; Matsuo M
Pediatr Res; 2006 May; 59(5):690-4. PubMed ID: 16627883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
